Santarus — Technical Presentation (May 2011)
24 slides from Santarus's technical presentation, May 9, 2011
Slide 1: Budesonide MMX 9 mg for induction of remission of mild-to-moderate ulcerative colitis
Budesonide MMX(r) 9 mg for the induction of remission of mild-to-moderate ulcerative colitis (UC): data from a multicenter, randomized, double-blind, placebo-controlled study in North America and India 9 May 2011 William J. Sandborn1, Simon Travis2, Luigi Moro3, E. David Ballard4, Philip Yeung4, Wil
Slide 2: Budesonide Properties
Budesonide Properties Budesonide Non-halogenated glucocorticoid structurally related to 16-hydroxyprednisolone that binds with high affinity to glucocorticoid receptors Greater topical anti-inflammatory activity but less systemic activity than other glucocorticoids due to high first pass metabolism
Slide 3: Summary of Human Pharmacokinetics of Budesonide MMX
Summary of Human Pharmacokinetics of Budesonide MMX(r) 3 To Systemic Distribution
Slide 4: Therapies for Ulcerative Colitis (UC) Current Limitations
Therapies for Ulcerative Colitis (UC) Current Limitations Conventional therapies often have limited sites of action Oral corticosteroids are effective but have systemic adverse effects Large daily pill burden; multiple doses per day 4 Oral treatments Enemas, suppositories and foams Site of action Be
Slide 5: Multi-matrix System (MMX)
Multi-matrix System (MMX(r)) Multi-matrix system (MMX(r)) - a unique technology Targeted drug delivery to entire colon, the site of UC Potential for efficacy of conventional steroid, while minimizing systemic side effects MMX(r) technology has previously been successfully applied to IBD (Lialda(r))
Slide 6: Budesonide MMX Comparative Pharmacokinetics
Budesonide MMX(r) Comparative Pharmacokinetics Bioavailability profile of budesonide MMX(r) (6 and 9 mg tablets) compared to a controlled ileal-release formulation, Entocort(r) EC 9 mg (3 x 3 mg) capsules in healthy volunteers 6 Entocort(r) EC 3 mg x 3 capsules Budesonide MMX 9 mg Budesonide MMX 6 m
Slide 7: Objectives
Objectives To evaluate the efficacy and safety of budesonide MMX(r) 6 and 9 mg/day in patients with mildly to moderately active ulcerative colitis 7
Slide 8: Study Design
Study Design 8 week randomized, double-blind, placebo-controlled, multicenter, parallel group trial 97 sites in 4 Countries (Canada, India, Mexico, and USA) Patients with mildly to moderately active ulcerative colitis Randomized in a 1:1:1:1 ratio to: Budesonide MMX(r) 6 mg/day Budesonide MMX(r) 9 m
Slide 9: Key Inclusion/Exclusion Criteria
Key Inclusion/Exclusion Criteria Male or female, 18-75 years History of UC for ^ 6 months Excluded patients with limited distal proctitis (from anal verge up to 15 cm above the pectineal line) Experiencing a mild or moderate flare of UC with an UC Disease Activity Index (UCDAI, Sutherland Index) sco
Slide 10: Evaluation of Efficacy: Primary Endpoint
Evaluation of Efficacy Individual Assessments (scored 0-3) Stool Frequency Rectal Bleeding Colonoscopy Physician's Rating of Disease Activity Primary Endpoint Remission at Week 8 defined as UCDAI score ^ 1 with: Rectal bleeding and stool frequency score = 0 AND Normal mucosa (no friability) on endos
Slide 11: Evaluation of Efficacy: Secondary Endpoints
Evaluation of Efficacy Secondary Endpoints Clinical Improvement Defined as a ^ 3 point reduction in UCDAI from Baseline to Week 8 Endoscopic Improvement Defined as a ^ 1 point reduction in the mucosal appearance score of the UCDAI from Baseline to Week 8 Other Endpoint Symptom Resolution Defined as
Slide 12: Statistical Analysis
Statistical Analysis Primary efficacy analysis Superiority of budesonide MMX(r) 6 mg or 9 mg versus placebo ^ = 0.025 (2-sided) Study not powered for comparisons of budesonide MMX(r) 6 mg versus budesonide MMX(r) 9 mg or budesonide MMX(r) 6 mg or 9 mg versus Asacol(r) Analysis performed on a pre-spe
Slide 13: Patient Disposition
Patient Disposition 13 20 patients excluded from modified ITT analysis 3 for major entry criteria violation 17 for normal histology at baseline Placebo 121 patients Budesonide MMX(r) 9 mg 123 patients Budesonide MMX(r) 6 mg 121 patients Asacol(r) 2.4 g 124 patients Modified ITT Population (N=489) Sa
Slide 14: Baseline Characteristics
Baseline Characteristics 14 N = 489 (modified ITT Population) Parameter PlaceboN = 121 MMX(r) 9 mgN = 123 MMX(r) 6 mgN = 121 Asacol(r) 2.4 g N = 124 Mean age (years) 41.0 41.5 43.7 43.8 Female gender (n [%]) 53 (43.8) 46 (37.4) 62 (51.2) 55 (44.4) Ulcerative colitis history Mean disease duration (ye
Slide 15: Remission at Week 8: Primary Efficacy Endpoint
Remission at Week 8 Primary Efficacy Endpoint 15 N=121 N=123 N=121 N=124 Remission, n(%) 9 (7.4) 22 (17.9) 16 (13.2) 15 (12.1) ^ vs. Placebo -- 10.4% 5.8% 4.7% P-value -- 0.0143* 0.1393 0.2200 * Statistically significant (p < 0.025) Not powered to show statistical difference between budesonide MMX(r
Slide 16: Remission at Week 8: Sensitivity Analysis
Remission at Week 8 Primary Efficacy Endpoint Sensitivity Analysis Sensitivity analysis in which all patients previously excluded from the modified ITT population (patients with major entry criteria violations and normal histology at baseline) were assigned to non- responder status 16 N = 509 (all r
Slide 17: Secondary Endpoints
Secondary Endpoints 17 N = 489 (modified ITT Population) * Clinical Improvement defined as a ^ 3 point reduction in UCDAI from Baseline to Week 8 + Endoscopic Improvement defined as a ^ 1 point reduction in the mucosal appearance score of the UCDAI from Baseline to Week 8; post hoc analysis Secondar
Slide 18: Other Endpoint - Symptom Resolution
Other Endpoint - Symptom Resolution (combined rectal bleeding and stool frequency scores of 0 at Week 8) 18 N=121 N=123 N=121 N=124 Symptom Resolution (yes), n(%) 20 (16.5) 35 (28.5) 35 (28.9) 31 (25.0) ^ vs. Placebo -- 11.9% 12.4% 8.5% P-value -- 0.0258* 0.0214* 0.1025 * Statistically significant (
Slide 19: Treatment-Emergent Adverse Events (TEAEs)
Treatment-Emergent Adverse Events (TEAEs) 19 N = 509 (all randomized patients who received at least one dose) 1 Related = Possibly or Probably related to study drug (or missing an assessment) 2 Derived from Action Taken to Study Drug = "Drug withdrawn" PlaceboN=129n (%) MMX(r) 9 mgN=127n (%) MMX(r)
Slide 20: Most Frequent TEAEs
Most Frequent TEAEs (^ 5% in any treatment group) 20 N = 509 (all randomized patients who received at least one dose) Preferred Term PlaceboN=129n (%) MMX(r) 9 mgN=127n (%) MMX(r) 6 mgN=126n (%) Asacol(r)N=127n (%) TotalN=509n (%) Patients with any TEAE 81 (62.8) 73 (57.5) 74 (58.7) 80 (63.0) 308 (6
Slide 21: Morning Plasma Cortisol
Morning Plasma Cortisol 21 Symbols indicate mean plasma cortisol level for each visit for each treatment. Error bars indicate 25th and 75th percentiles. Treatments are offset for readability. Numbers at the bottom of the graph are the number of patients at each visit that had plasma cortisol levels
Slide 22: Morning Plasma Cortisol: Budesonide CIR versus Prednisolone in Crohn's Disease
Morning Plasma Cortisol Budesonide CIR versus Prednisolone in Crohn's Disease 22 Rutgeerts P et al., NEJM, Vol 331, No 13, Sept 29. 1994
Slide 23: Signs and Symptoms of Glucocorticoid Effects
Signs and Symptoms of Glucocorticoid Effects* 23 N = 509 (all randomized patients who received at least one dose) Effect PlaceboN=129n (%) MMX(r) 9 mgN=127n (%) MMX(r) 6 mgN=126n (%) Asacol(r)N=127n (%) Overall 13 (10.1) 14 (11.1) 6 (4.8) 10 (7.9) Moon Face 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8) Striae Rub
Slide 24: Conclusions
Conclusions Budesonide MMX(r) 9 mg administered once daily was safe and effective for inducing remission in patients with mildly-to-moderately active UC Remission with budesonide MMX(r) 9 mg was superior to placebo (17.9% versus 7.4%; p-value = 0.0143) No significant differences between the study gr